1. Scrip
  2. >>Business
  3. >>Deals

MorphoSys Hits Refresh Button On Pipeline With Constellation Buy

Deal Worth $1.7bn Financed Through $2bn Partnership With Royalty

 
• By Alaric DeArment

The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.

Businessman and Businesswoman pressing Refresh Button
MorphoSys said 2 June it would acquire Constellation Pharmaceuticals for $1.7bn • Source: Shutterstock

Already looking at ways to expand to compete with major players in biotech after the launch of its first product in the US, European biotech MorphoSys AG is beefing up its pipeline with two mid- and late-stage epigenetic compounds with the $1.7bn acquisition of Constellation Pharmaceuticals, Inc.. The deal, which includes a novel financing partnership with Royalty Pharma plc, may also portend a pickup in the speed of M&A for 2021.

MorphoSys, based near Munich, Germany, and Cambridge, MA-based Constellation announced the $34-per-share deal on 2 June, which both companies’ boards...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

 
• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By Mandy Jackson

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

More from Business

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

 
• By Alaric DeArment and Sarah Karlin-Smith

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.

Replimune CRL Could Hold Warning For Accelerated Approvals

 
• By Jessica Merrill

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.